Arcus Biosciences to Participate in Two Upcoming March 2024 Investor Conferences

2024-02-28

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Biopharma Conference 2024 Date: Monday, March 11th, 2024 at 4:00 p.m. ET Location: Miami Beach, FL Format: Fireside Chat Barclays 26th Annual Global Healthcare Conference Date: Tuesday, March 12th, 2024 at 2:35 p.m. ET Location: Miami Beach, FL Format: Fireside Chat Live webcasts of the fireside chats and panel will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at . Replays will be available following each live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73, dual A2a/A2b receptor and CD39), AXL and HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit or follow us on X. View source version on businesswire.com: Contacts Investor Inquiries Pia Eaves VP of Investor Relations & Strategy (617) 459-2006 peaves@arcusbio.com Media Inquiries Holli Kolkey VP of Corporate Communications (650) 922-1269 hkolkey@arcusbio.com Source: Arcus Biosciences View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构